Switching from fingolimod to alemtuzumab in patients with highly active relapsing-remitting multiple sclerosis: Α case series.

[1]  M. Sormani,et al.  Outcomes after fingolimod to alemtuzumab treatment shift in relapsing–remitting MS patients: a multicentre cohort study , 2019, Journal of Neurology.

[2]  S. Schmidt,et al.  Severe rebound after cessation of fingolimod treated with ocrelizumab with coincidental transient aggravation: report of two cases , 2019, Therapeutic advances in neurological disorders.

[3]  S. Gil-Perotín,et al.  Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing–remitting multiple sclerosis is effective and safe , 2019, Journal of Neurology.

[4]  V. Meca-Lallana,et al.  Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases. , 2018, Multiple sclerosis and related disorders.

[5]  R. Grasso,et al.  Clinical activity after fingolimod cessation: disease reactivation or rebound? , 2018, European journal of neurology.

[6]  R. Gold,et al.  Alemtuzumab as rescue therapy in a cohort of 50 relapsing–remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study , 2018, Journal of Neurology.

[7]  Ó. Fernández.  Is there a change of paradigm towards more effective treatment early in the course of apparent high-risk MS? , 2017, Multiple sclerosis and related disorders.

[8]  P. Vermersch,et al.  A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo , 2017, Multiple sclerosis journal - experimental, translational and clinical.

[9]  M. Duddy,et al.  An observational study of alemtuzumab following fingolimod for multiple sclerosis , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[10]  Simone Faller,et al.  Th17 cells: A prognostic marker for MS rebound after natalizumab cessation? , 2017, Multiple sclerosis.

[11]  E. Waubant,et al.  Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. , 2016, JAMA neurology.

[12]  A. Lapucci,et al.  Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound , 2015, Brain, Behavior, and Immunity.